BioArctic AB (publ)
BRCTFOTCHealthcare● Active
$35.00
+$0.00(+0.00%)
Market Cap$3.1B
P/E Ratio—
52W High$38.75
52W Low$18.74
BioArctic AB (publ) (BRCTF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BRCTF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 20, 2026EPS Actual
$0.25
Est. -$0.03 · +896.6%
Revenue
$0.05B
Est. $0.02B · +127.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 20, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
BRCTF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 26, 2026 | -$0.04 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 20, 2026 | -$0.03 | $0.25 | +896.6% | $0.05B | $0.02B | +127.2% |
| ▲ Q1 FY2026 | Feb 18, 2026 | -$0.06 | -$0.01 | +81.5% | $0.02B | $0.02B | +10.2% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.12 | -$0.10 | +13.8% | $0.00B | $0.02B | -91.7% |
| ▼ Q2 FY2025 | Jun 30, 2025 | $0.16 | $0.11 | -29.6% | $0.04B | $0.04B | +6.3% |
| ▲ Q1 FY2025 | Mar 31, 2025 | $1.03 | $1.15 | +11.7% | $0.13B | $0.13B | +1.4% |
| ▲ Q4 FY2024 | Dec 31, 2024 | -$0.06 | -$0.03 | +43.9% | $0.01B | $0.01B | +2.9% |
| ▲ Q3 FY2024 | Sep 30, 2024 | -$0.06 | -$0.02 | +64.8% | $0.01B | $0.01B | +2.3% |
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
-$0.04
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 20, 2026Beat
EPS Actual
$0.25
EPS Est.
-$0.03
EPS Surpr.
+896.6%
Revenue
$0.05B
Q1 FY2026
Feb 18, 2026Beat
EPS Actual
-$0.01
EPS Est.
-$0.06
EPS Surpr.
+81.5%
Revenue
$0.02B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.12
EPS Surpr.
+13.8%
Revenue
$0.00B
Q2 FY2025
Jun 30, 2025Miss
EPS Actual
$0.11
EPS Est.
$0.16
EPS Surpr.
-29.6%
Revenue
$0.04B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
$1.15
EPS Est.
$1.03
EPS Surpr.
+11.7%
Revenue
$0.13B
Q4 FY2024
Dec 31, 2024Beat
EPS Actual
-$0.03
EPS Est.
-$0.06
EPS Surpr.
+43.9%
Revenue
$0.01B
Q3 FY2024
Sep 30, 2024Beat
EPS Actual
-$0.02
EPS Est.
-$0.06
EPS Surpr.
+64.8%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $6.33 | $6.94 | $7.60 | 1 |
| Q3 FY2027 | $1.19 | $1.31 | $1.43 | 1 |
| Q2 FY2027 | $5.23 | $5.73 | $6.28 | 1 |
| Q1 FY2027 | $0.28 | $0.30 | $0.33 | 1 |
| Q4 FY2026 | $1.09 | $1.19 | $1.31 | 1 |
| Q3 FY2026 | $-0.10 | $-0.09 | $-0.08 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.0B | $1.1B | $1.2B | 3 |
| Q3 FY2027 | $0.4B | $0.4B | $0.5B | 2 |
| Q2 FY2027 | $0.9B | $0.9B | $1.0B | 2 |
| Q1 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q4 FY2026 | $0.3B | $0.3B | $0.4B | 3 |
| Q3 FY2026 | $0.2B | $0.2B | $0.3B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 20, 2026 | +896.6% | $33.02 | $33.02 | +0.00% |
| ▲ Q1 FY2026 | Feb 18, 2026 | +81.5% | $33.14 | $40.00 | +20.70% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +13.8% | $27.82 | $27.82 | +0.00% |
| ▼ Q2 FY2025 | Jun 30, 2025 | -29.6% | $19.34 | $19.34 | +0.00% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +11.7% | $18.12 | $18.12 | +0.00% |
| ▲ Q4 FY2024 | Dec 31, 2024 | +43.9% | $18.30 | $18.30 | +0.00% |
| ▲ Q3 FY2024 | Sep 30, 2024 | +64.8% | $16.04 | $15.56 | -2.99% |
| ▼ Q2 FY2024 | Jun 30, 2024 | -2.7% | No price data | $22.00 | — |
Q2 FY2026+0.00%
Report Date
May 20, 2026
EPS Beat/Miss
+896.6%
Price Before
$33.02
Price After
$33.02
Q1 FY2026+20.70%
Report Date
Feb 18, 2026
EPS Beat/Miss
+81.5%
Price Before
$33.14
Price After
$40.00
Q4 FY2025+0.00%
Report Date
Nov 13, 2025
EPS Beat/Miss
+13.8%
Price Before
$27.82
Price After
$27.82
Q2 FY2025+0.00%
Report Date
Jun 30, 2025
EPS Beat/Miss
-29.6%
Price Before
$19.34
Price After
$19.34
Q1 FY2025+0.00%
Report Date
Mar 31, 2025
EPS Beat/Miss
+11.7%
Price Before
$18.12
Price After
$18.12
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
+43.9%
Price Before
$18.30
Price After
$18.30
Q3 FY2024-2.99%
Report Date
Sep 30, 2024
EPS Beat/Miss
+64.8%
Price Before
$16.04
Price After
$15.56
Q2 FY2024—
Report Date
Jun 30, 2024
EPS Beat/Miss
-2.7%
Price Before
—
Price After
$22.00
Avg Beat Reaction+2.95%
Avg Miss Reaction+0.00%
Beat Rate6 / 8 quarters
Largest Move+20.70% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BRCTF ends December
BioArctic AB (publ) (BRCTF) most recently reported earnings on May 20, 2026 for Q2 FY2026, posting EPS of $0.25 — beating the analyst consensus of $-0.03 by +896.6%. BRCTF has beaten EPS estimates for 3 consecutive quarters. The next BRCTF earnings date is expected around September 1, 2026.
Each quarter, investors track BRCTF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BRCTF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BRCTF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BRCTF earnings · 5 questionsBioArctic AB (publ)'s next earnings report is expected around September 1, 2026. BRCTF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BRCTF historically reports after market close (AMC).
BRCTF earnings datewhen is BRCTF earningsBRCTF next earnings datewhen does BRCTF report earningsBRCTF earnings calendar
▸ Source: FMP · BioArctic AB (publ) SEC filings · US GAAP · BioArctic AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026